Levodopa improves motor deficits but can further disrupt cognition in a macaque Parkinson model.

Jay S. Schneider, Elsa Y. Pioli, Yang Jianzhong, Qin Li, Erwan Bezard
Mov Disord.. 2012-12-12; 28(5): 663-667
DOI: 10.1002/mds.25258

PubMed
Lire sur PubMed





1. Mov Disord. 2013 May;28(5):663-7. doi: 10.1002/mds.25258. Epub 2012 Dec 12.

Levodopa improves motor deficits but can further disrupt cognition in a macaque
Parkinson model.

Schneider JS(1), Pioli EY, Jianzhong Y, Li Q, Bezard E.

Author information:
(1)Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson
University, Philadelphia, PA 19107, USA. *protected email*

Comment in
Mov Disord. 2013 May;28(5):563-4.

BACKGROUND: Levodopa effectively relieves motor symptoms in Parkinson’s disease
(PD), but has had inconsistent effects on cognition, even worsening some aspects
of cognitive functioning. Therefore, remediation of PD cognitive deficits is a
major unmet need. However, drug development efforts have been hampered by lack of
an animal model in which motor and cognitive deficits can be examined
simultaneously.
METHODS: Cynomolgus monkeys were trained to perform cognitive tasks and then
chronically exposed to MPTP to slowly produce cognitive and motor deficits of
parkinsonism.
RESULTS: Administration of L-dopa to these animals dose dependently improved
motor functioning, but did not significantly improve cognitive performance. At
doses that maximally improved motor function, additional cognitive deficits were
observed. The present model of MPTP-induced parkinsonism recapitulates important
motor and cognitive aspects of PD. Results with L-dopa mirror data derived from
PD patients.
CONCLUSION: This model should allow more efficient testing of potential PD
therapeutics to evaluate motor and cognitive functions simultaneously. © 2012
Movement Disorder Society.

Copyright © 2012 Movement Disorders Society.

DOI: 10.1002/mds.25258
PMID: 23238827 [Indexed for MEDLINE]


Auteurs Bordeaux Neurocampus